SCHEMBL6097008

SCHEMBL6097008

O=C(N1CCc2cccc([N+](=O)[O-])c2CC1)C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.48
RAB9A P51151 3/20 0.45
AKR1C3 P42330 1/20 0.44
AKR1C1 Q04828 1/20 0.44
ABHD6 Q9BV23 4/20 0.44
ESR1 P03372 2/20 0.42
ESR2 Q92731 2/20 0.42
ALDH1A1 P00352 2/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
PDE4B Q07343 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
NPC1 O15118 1/20 0.40
GAA P10253 1/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
HTR2B P41595 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6095657 0.83 HPGD (0.52) HPGDRAB9AAKR1C3AKR1C1ALDH1A1
SCHEMBL721253 0.80 ESR1 (0.51) HPGDRAB9AABHD6ESR1ESR2
SCHEMBL506963 0.79 ESR1 (0.50) AKR1C3AKR1C1ABHD6ESR1ESR2
SCHEMBL6098293 0.79 HPGD (0.48) HPGDRAB9AAKR1C3AKR1C1ALDH1A1
SCHEMBL6096546 0.79 ALDH1A1 (0.53) HPGDRAB9AAKR1C3AKR1C1ESR2
SCHEMBL6098283 0.78 ESR1 (0.46) RAB9AAKR1C3ABHD6ESR1ESR2
SCHEMBL506139 0.76 ESR1 (0.59) HPGDRAB9AABHD6ESR1ESR2
SCHEMBL7420066 0.76 MEN1 (0.47) HPGDESR1ESR2ALDH1A1MAPT
SCHEMBL17197463 0.76 NOTUM (0.55) HPGDRAB9AAKR1C3AKR1C1ALDH1A1
SCHEMBL2566648 0.76 ESR1 (0.50) HPGDRAB9AABHD6ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7022694-B2 Indoles and indolines having 5-HT activity PHARMACIA & UPJOHN COMPANY (US) 2006-04-04 US disclosed
EP-1406902-B1 HEXAHYDROAZEPINO[4,5-G]INDOLES AND INDOLINES AS 5-HT RECEPTOR LIGANDS PHARMACIA & UPJOHN CO LLC (US) 2005-10-19 EP disclosed
EP-1406902-A1 HEXAHYDROAZEPINO(4,5-G)INDOLES AND INDOLINES AS 5-HT RECEPTOR LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2004-04-14 EP disclosed
US-20030060458-A1 Indoles and indolines having 5-HT activity PHARMACIA & UPJOHN COMPANY 2003-03-27 US disclosed
WO-2003006466-A1 HEXAHYDROAZEPINO (4, 5-G) INDOLES AND INDOLINES AS 5-HT RECEPTOR LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2003-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060458-A1 Indoles and indolines having 5-HT activity TPH1, HTR5A, TPH2 HPGD 1569/4885RAB9A 1373/4885AKR1C3 993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.